Holen Sie sich die Stockscreener-App
0.2479
7.43%
-0.0199
Handel nachbörslich:
.27
0.0221
+8.91%
Schlusskurs vom Vortag:
$0.2678
Offen:
$0.27
24-Stunden-Volumen:
668.22K
Relative Volume:
0.87
Marktkapitalisierung:
$18.11M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-31.88M
KGV:
-0.3305
EPS:
-0.75
Netto-Cashflow:
$-25.20M
1W Leistung:
-13.56%
1M Leistung:
-7.84%
6M Leistung:
-70.09%
1J Leistung:
-81.64%
1-Tages-Spanne:
$0.2433
$0.27
1-Wochen-Bereich:
$0.2433
$0.285
52-Wochen-Spanne:
$0.217
$1.74
In 8 Bio Inc Stock (INAB) Company Profile
Firmenname
In 8 Bio Inc
Sektor
Branche
Telefon
(646) 600-6438
Adresse
EMPIRE STATE BUILDING, NEW YORK
Vergleichen Sie INAB mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INAB
In 8 Bio Inc
|
0.2479 | 18.11M | 0 | -31.88M | -25.20M | -0.75 |
|
VRTX
Vertex Pharmaceuticals Inc
|
438.40 | 113.67B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
683.08 | 74.97B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
665.68 | 40.50B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
277.16 | 35.95B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
120.88 | 29.63B | 3.30B | -501.07M | 1.03B | -2.1146 |
In 8 Bio Inc Stock (INAB) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-03-18 | Eingeleitet | Laidlaw | Buy |
| 2022-08-30 | Eingeleitet | H.C. Wainwright | Buy |
In 8 Bio Inc Aktie (INAB) Neueste Nachrichten
Palisade Bio Selected for Poster Presentation at the 2025 Crohn’s & Colitis Congress - Yahoo Finance UK
Breakeven On The Horizon For Belite Bio, Inc (NASDAQ:BLTE) - Yahoo Finance UK
Cabaletta Bio Discloses Unaudited Cash and Cash Equivalents of $164 Million as of December 31, 2024 - Defense World
Palisade Bio Completes All Five SAD Cohorts and Advances to - GlobeNewswire
Vyant Bio (OTCMKTS:VYNT) Shares Up 7.8% – Time to Buy? - Defense World
Mustang Bio Announces Reverse Stock Split - GlobeNewswire
Passage Bio (NASDAQ:PASG) Announces Restructuring Plan and Financial Update - Defense World
Annovis Bio, Inc. (NYSE:ANVS) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Cadenza Bio, Inc. Announces Members of the Women's Health Scientific Advisory Board - Chicago Star Media
Pivot Bio Announces Ryan Degnan as Head of Growth - PR Newswire
Adicet Bio Provides Corporate Update - TradingView
Adicet Bio Provides Corporate Update and Highlights Expected 2025 Milestones - The Bakersfield Californian
7 Best Biotech Stocks to Buy for 2025 | Investing - U.S News & World Report Money
INmune Bio: Phase 2 Trial In Alzheimer's Disease Is My Highest Risk-Reward Bet Of 2025 - Seeking Alpha
Geode Capital Management LLC Increases Holdings in Nuvation Bio Inc. (NYSE:NUVB) - MarketBeat
KALA BIO Announces Private Placement Agreement with Institutional Investors - Defense World
KALA BIO Announces $10,750,000 Private Placement - GlobeNewswire
bluebird bio, Inc. (BLUE): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds - Yahoo Finance
**BioAtla Updates Corporate Presentation in 8-K Filing** - Defense World
Tolerance Bio, Inc. Announces Scientific Advisory Board and Completion of $20.2 Million Seed Round to Advance Thymus-Based Therapies for Immune-Mediated Diseases - Business Wire
Palisade Bio Appoints Brian Feagan, MD, FRCPC, to its Clinical Advisory Board - GlobeNewswire
Annovis Bio 8-K Filing Reveals Investor Update and Presentation Details - Defense World
Hamps Bio share price hits 5% upper circuit after listing at 90% premium - Mint
INmune Bio Inc. Completes Repayment of Silicon Valley Bank Debt - The Manila Times
INmune Bio Strengthens Balance Sheet Ahead of Crucial Alzheimer's Trial Data, Clears $15M Debt - StockTitan
Suven Pharma acquires 56% stake in US-based NJ Bio - The Times of India
Hyderabad's Suven to acquire controlling stake in Princeton based NJ Bio, Inc - Deccan Herald
GRI Bio to Participate in the Virtual Investor Closing Bell Series - GlobeNewswire
PRUDENTIAL FINANCIAL INC's Strategic Acquisition of Cabaletta Bio Inc Shares - GuruFocus.com
bluebird bio Announces 1-for-20 Reverse Stock Split - Business Wire
/C O R R E C T I O N -- Today's Marketplace/ - Quantisnow
Palisade Bio Announces Preliminary Data from Phase 1 Clinical Study of PALI-2108 for the Treatment of Moderate-to-Severe Ulcerative Colitis Appears to be Safe and Well Tolerated in Treated Subjects - GlobeNewswire
KALA BIO to Present at Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
Kronos Bio : Management Change/Compensation Form 8 K - Marketscreener.com
Attendee List for BevNET Live Winter 2024 - BevNET.com
Tevogen Bio Prepares Organizational Readiness to Support Company’s Growth Strategy - GlobeNewswire
Annovis to Host Year-End Investor Webcast on December 11, 2024 - Quantisnow
Advantage Therapeutics Inc. Announces Formation of Klothea Bio, Inc. to Advance Research and Development of Klotho Protein for Age-Related Therapeutics - Yahoo Finance
GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF) - The Manila Times
GRI Bio Showcases GRI-0621’s Potential to Reduce - GlobeNewswire
Palisade Bio to Present Preclinical Results for PALI-2108 - GlobeNewswire
10 Biggest Biotechnology Companies - Investopedia
TāStation®'s analytical power used to resolve a central question about sweet taste perception - EurekAlert
Cabaletta Bio Presents Positive Clinical Safety and Efficacy Data on CABA-201 at ACR Convergence 2024 - The Manila Times
Intevac (NASDAQ: IVAC) Enters into Letter Agreement with Palogic Value Management, L.P.Santa Clara, CA, November 13, 2024 – Intevac, Inc. (NASDAQ: IVAC) disclosed today in a Form 8-K filing that on November 8, 2024, the company entered into a letter - Defense World
Sound Point Meridian Capital, Inc. (NYSE: SPMC) Announces Financial Results for Quarter Ended September 30, 2024 - Defense World
Roth CH Acquisition II Files 8-K Report with SEC Detailing Company Updates and Investor Presentation - Defense World
Capricor Therapeutics Announces Financial Results for Third Quarter 2024 and Strategic DevelopmentsSAN DIEGO, November 13, 2024 (GLOBE NEWSWIRE) — Capricor Therapeutics (NASDAQ: CAPR) recently disclosed its financial outcomes for the third - Defense World
Predictive Oncology Inc. Issues Press Release Detailing Financial Results for Q3 2024Predictive Oncology Inc., a leading biopharmaceutical company, released a pivotal press release detailing its financial results for the quarter ending September 30 - Defense World
Broadwind, Inc. Reports Financial Results for Quarter Ending September 30, 2024 - Defense World
Finanzdaten der In 8 Bio Inc-Aktie (INAB)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.49%
0.79%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):